undamentalytics Newsletter

Rigel Pharmaceuticals Inc cash flow statement

In fiscal 2025, Rigel Pharmaceuticals Inc's operations generated $75.7m of cash; it spent $0 on capital projects, leaving free cash flow of $75.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Rigel Pharmaceuticals Inc: cash flow statement, annual
Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−76−78−59−42−526−74−6317679
Depreciation and amortisation10111111223
Stock-based pay768979129121316
Capital spending10111100000
Free cash flow−77−78−60−43−535−74−6317679
Free cash flow after stock pay−84−84−68−52−61−4−87−15196363
Shares issued2411467————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: HROW vs RIGLEOLS vs RIGLACB vs RIGL

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Rigel Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rigel Pharmaceuticals Inc.